The incidence of psychosis during clinical trials of topiramate was 0.8%, not significantly different from the rate for placebo
or reported rates of psychosis in patients with refractory epilepsy. We observed psychotic symptoms in five patients soon after
initiation of topiramate therapy. We performed a retrospective chart review of the first 80 patients who began on topiramate
after approval for clinical use, between January and April 1997. Symptoms suggestive of psychosis, including hallucinations
and delusions, were sought for analysis. Cognitive effects such as psychomotor slowing, confusion, and somnolence were not
included. Five patients developed definite psychotic symptoms 2 to 46 days after beginning topiramate. Dosages at symptom onset
were 50–400 mg/day. Symptoms included paranoid delusions in four patients and auditory hallucinations in three. Symptoms of
psychosis and other psychiatric symptoms resolved quickly with discontinuation of topiramate in three patients, dose reduction
from 300 to 200 mg/day in one and with inpatient treatment and neuroleptics in another. One patient had a history of auditory
hallucinations, one of aggressive and suicidal thoughts, but three had no significant psychiatric history. Physicians should be aware
of the possibility of psychotic symptoms, even in patients without a previous psychiatric history, when prescribing topiramate.
Symptoms resolve quickly with discontinuation.
The incidence of psychosis during clinical trials of topiramate was 0.8%, not significantly different from the rate for placeboor reported rates of psychosis in patients with refractory epilepsy. We observed psychotic symptoms in five patients soon afterinitiation of topiramate therapy. We performed a retrospective chart review of the first 80 patients who began on topiramateafter approval for clinical use, between January and April 1997. Symptoms suggestive of psychosis, including hallucinationsand delusions, were sought for analysis. Cognitive effects such as psychomotor slowing, confusion, and somnolence were notincluded. Five patients developed definite psychotic symptoms 2 to 46 days after beginning topiramate. Dosages at symptom onsetwere 50–400 mg/day. Symptoms included paranoid delusions in four patients and auditory hallucinations in three. Symptoms ofpsychosis and other psychiatric symptoms resolved quickly with discontinuation of topiramate in three patients, dose reductionfrom 300 to 200 mg/day in one and with inpatient treatment and neuroleptics in another. One patient had a history of auditoryhallucinations, one of aggressive and suicidal thoughts, but three had no significant psychiatric history. Physicians should be awareof the possibility of psychotic symptoms, even in patients without a previous psychiatric history, when prescribing topiramate.Symptoms resolve quickly with discontinuation.
การแปล กรุณารอสักครู่..
The incidence of psychosis during clinical trials of topiramate was 0.8%, not significantly different from the rate for placebo
or reported rates of psychosis in patients with refractory epilepsy. We observed psychotic symptoms in five patients soon after
initiation of topiramate therapy. We performed a retrospective chart review of the first 80 patients who began on topiramate
after approval for clinical use, between January and April 1997. Symptoms suggestive of psychosis, including hallucinations
and delusions, were sought for analysis. Cognitive effects such as psychomotor slowing, confusion, and somnolence were not
included. Five patients developed definite psychotic symptoms 2 to 46 days after beginning topiramate. Dosages at symptom onset
were 50–400 mg/day. Symptoms included paranoid delusions in four patients and auditory hallucinations in three. Symptoms of
psychosis and other psychiatric symptoms resolved quickly with discontinuation of topiramate in three patients, dose reduction
from 300 to 200 mg/day in one and with inpatient treatment and neuroleptics in another. One patient had a history of auditory
hallucinations, one of aggressive and suicidal thoughts, but three had no significant psychiatric history. Physicians should be aware
of the possibility of psychotic symptoms, even in patients without a previous psychiatric history, when prescribing topiramate.
Symptoms resolve quickly with discontinuation.
การแปล กรุณารอสักครู่..